Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Br J Dermatol
    October 2026
  1. RAMAMURTHY SRINIVASAN M, de Berker D, Venables ZC, Levell NJ, et al
    The environmental burden of melanoma: a national stage-specific carbon footprint analysis.
    Br J Dermatol. 2026 Oct 8:ljag440. doi: 10.1093.
    >> Share

  2. ADALSTEINSSON JA, Karadottir HL
    Surviving stage IV melanoma: the unfinished task of survivorship care.
    Br J Dermatol. 2026 Oct 5:ljag438. doi: 10.1093.
    >> Share

  3. BELL KJL, Adamson AS, Parker L, van Akkooi ACJ, et al
    Goals of melanoma surveillance: focusing on outcomes that matter most.
    Br J Dermatol. 2026 Oct 1:ljag430. doi: 10.1093.
    >> Share

    September 2026
  4. BALADO-SIMO P, Podlipnik S
    Low-risk lesion, increased-risk patient: separating lesion prognosis from future melanoma risk.
    Br J Dermatol. 2026 Sep 30:ljag427. doi: 10.1093.
    >> Share

  5. REITMAJER M, Livingstone E, Schaffeler N, Borger S, et al
    Beyond the Surface of Long-term Survival in Stage IV Melanoma: A Multicenter Cross-sectional Study.
    Br J Dermatol. 2026 Sep 19:ljag374. doi: 10.1093.
    >> Share

  6. LU S, Micevic G, McGrath JA
    Personalised mRNA Therapy Comes of Age in Melanoma.
    Br J Dermatol. 2026 Sep 8:ljag378. doi: 10.1093.
    >> Share

    August 2026
  7. ZHANG J, Wang H, Zheng Q, Liu M, et al
    High-dimensional overfitting and noisy diagnostic labels: reconsidering the role of BRAF copy number in primary dermal melanoma.
    Br J Dermatol. 2026 Aug 24:ljag348. doi: 10.1093.
    >> Share

  8. ZHAO P, Papenfuss AT, Shackleton M
    Reply to 'High-dimensional overfitting and noisy diagnostic labels: reconsidering the role of BRAF copy number in primary dermal melanoma'.
    Br J Dermatol. 2026 Aug 21:ljag346. doi: 10.1093.
    >> Share

  9. BELL KJL, Wu Z, Boroumand F, Parker L, et al
    Alternative diagnostic labels for melanoma in-situ: a randomised online experiment.
    Br J Dermatol. 2026 Aug 17:ljag341. doi: 10.1093.
    >> Share

  10. LIN Y, Su H, Lin J, Chen Y, et al
    Lifetime Risk of Cutaneous Melanoma in 185 Countries: Decomposing its Difference From Cumulative Risk into Methodological and Longevity Effects.
    Br J Dermatol. 2026 Aug 14:ljag336. doi: 10.1093.
    >> Share

    July 2026
  11. MISTRY K, Levell NJ, Karponis D, Wakkee M, et al
    Trends in keratinocyte cancers in England, 2013-2022: basal cell carcinoma incidence, cutaneous squamous cell carcinoma incidence, and non-melanoma skin cancer mortality.
    Br J Dermatol. 2026 Jul 28:ljag315. doi: 10.1093.
    >> Share

  12. LODDE G, Livingstone E, Stang A
    Melanoma of unknown primary: UV-driven genomics and the need for era-adjusted outcomes: reply from authors.
    Br J Dermatol. 2026 Jul 23:ljag292. doi: 10.1093.
    >> Share

    June 2026
  13. BOADA A, Tejera-Vaquerizo A
    Melanoma diagnosis during COVID-19: delay, disruption and the question of overdiagnosis.
    Br J Dermatol. 2026 Jun 7:ljag234. doi: 10.1093.
    >> Share

  14. FORCEY DS, Rosales BM, Wyld ML, De La Mata N, et al
    Skin cancer mortality in Australian and New Zealand kidney transplant recipients: A population-based cohort study using linked health data, 1990-2019.
    Br J Dermatol. 2026 Jun 4:ljag232. doi: 10.1093.
    >> Share

  15. DE GIORGI V, Perillo G, Cecchi G, Fazzari F, et al
    Melanoma of unknown primary: UV-driven genomics and the need for era-adjusted outcomes.
    Br J Dermatol. 2026 Jun 1:ljag224. doi: 10.1093.
    >> Share

    May 2026

  16. Correction to: A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021.
    Br J Dermatol. 2026 May 21:ljag197. doi: 10.1093.
    >> Share

  17. THOMAS NE, Kanetsky PA
    Enhanced Polygenic Risk Scores for Melanoma Prediction.
    Br J Dermatol. 2026 May 21:ljag185. doi: 10.1093.
    >> Share

  18. COLLARD MK, Belkadi-Sadou D, Cavalcanti A, Lesourd R, et al
    Immune checkpoint inhibitors in anorectal melanoma: has it changed the outcomes?
    Br J Dermatol. 2026 May 20:ljag204. doi: 10.1093.
    >> Share

  19. MCGRATH JA, Olsen CM
    Mole counts, melanoma, and the dermatologist's next "vital sign".
    Br J Dermatol. 2026 May 9:ljag178. doi: 10.1093.
    >> Share

  20. KARPONIS D, Nikolaou V, Stratigos AJ, Mistry K, et al
    Epidemiology of lentigo maligna and lentigo maligna melanoma in England between 2013-2023.
    Br J Dermatol. 2026 May 8:ljag177. doi: 10.1093.
    >> Share

  21. MARJANOVIC M, Claeson M
    Type 2 diabetes in melanoma patients: a potential prognostic risk factor?
    Br J Dermatol. 2026 May 7:ljag173. doi: 10.1093.
    >> Share

  22. SAND C, Jayasinghe D, Wolfe R, Mar V, et al
    Evaluating COVID-19 Pandemic Impact on Melanoma Incidence and factors in Regions with Different Infection Control Strategies.
    Br J Dermatol. 2026 May 4:ljag172. doi: 10.1093.
    >> Share

    April 2026
  23. MIKIVER R, Marjanovic M, Nielsen K, Isaksson K, et al
    Impact of occult metastasis size on mortality in stage IIIA melanoma: A Swedish population-based registry study.
    Br J Dermatol. 2026 Apr 30:ljag171. doi: 10.1093.
    >> Share

  24. ZOUTENDIJK J, Hollestein LM, Mooyaart AL, Wakkee M, et al
    A nationwide study of treatment of lentigo maligna and its recurrence rate in the Netherlands.
    Br J Dermatol. 2026;194:862-868.
    >> Share

  25. WANG H, Ghajari H, Jayasinghe GJMSR, Seviiri M, et al
    Genetics vs clinical risk scores for melanoma prediction.
    Br J Dermatol. 2026 Apr 10:ljag126. doi: 10.1093.
    >> Share

    March 2026

  26. Correction to: Contrasting survival outcomes and patient characteristics in 5815 patients with stage II and III melanoma: a nationwide population-based registry study from Sweden.
    Br J Dermatol. 2026 Mar 21:ljag096. doi: 10.1093.
    >> Share

  27. LYNGSTRAND JE, Rossell EL, Bonnelykke-Behrndtz ML, Laurberg T, et al
    The impact of type 2 diabetes on sex- and stage-specific melanoma recurrence and mortality: A Danish cohort study, 2004 to 2024.
    Br J Dermatol. 2026 Mar 15:ljag097. doi: 10.1093.
    >> Share

    February 2026
  28. BOOTH L, Chen X, Stoker K, McCraw A, et al
    Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: A scoping review.
    Br J Dermatol. 2026 Feb 26:ljag074. doi: 10.1093.
    >> Share

  29. MARJANOVIC M, Mikiver R, Nielsen K, Isaksson K, et al
    Comment on 'Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma: A Nationwide Population-Based Registry Study from Sweden': reply from authors.
    Br J Dermatol. 2026 Feb 25:ljag059. doi: 10.1093.
    >> Share

  30. LODDE G, Dollani J, Galetzka W, Mohr P, et al
    Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma.
    Br J Dermatol. 2026 Feb 20:ljaf499. doi: 10.1093.
    >> Share

  31. KIPS J, Papeleu J, Shen A, Mylle S, et al
    Artificial intelligence-based smartphone application for skin cancer detection: A prospective diagnostic accuracy study.
    Br J Dermatol. 2026 Feb 17:ljag057. doi: 10.1093.
    >> Share

  32. BEAGLES E, Khattab S, Burke OM, Nguyen N, et al
    The Impact of Clinicopathologic Features on the Prognosis of Thin Melanomas: A Retrospective Cohort Analysis.
    Br J Dermatol. 2026 Feb 2:ljag034. doi: 10.1093.
    >> Share

    January 2026
  33. QI J, Nie G
    Comment on 'Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma: A Nationwide Population-Based Registry Study from Sweden'.
    Br J Dermatol. 2026 Jan 28:ljag030. doi: 10.1093.
    >> Share

  34. CUI X, Wang Y, Liu S, Zhang Q, et al
    A novel fusion gene identified in metastatic melanoma associated with malignant transformation of a giant congenital melanocytic naevus.
    Br J Dermatol. 2026 Jan 14:ljag015. doi: 10.1093.
    >> Share

  35. MORTAGY M, Cliff-Patel N, Askary R, Bologan AM, et al
    Evaluation and Enhancement of the Prognostic Ability of the Eighth Edition of TNM Staging in Cutaneous Malignant Melanoma: A Population-Based Study of 111,871 Cases Using Machine Learning.
    Br J Dermatol. 2026 Jan 13:ljag018. doi: 10.1093.
    >> Share

  36. REYES-MARCELINO G, Salam RA, Espinoza D, Watts CG, et al
    Real-world evaluation of the use of melanoma risk prediction tools by clinicians in Australia: a mixed methods study.
    Br J Dermatol. 2026 Jan 8:ljag003. doi: 10.1093.
    >> Share

  37. GHIASVAND R
    High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma?
    Br J Dermatol. 2026 Jan 3:ljaf523. doi: 10.1093.
    >> Share

    December 2025
  38. BAIRD J, Murrell D
    P22 Using VECTRA and AI analysis to monitor paediatric lesions: a review of cases.
    Br J Dermatol. 2025;193.
    >> Share

  39. KAHLER S, Yan S, Mothershaw A, Leo F, et al
    Automated classification of site-specific cutaneous photodamage using a convolutional neural network and 3D total body photography.
    Br J Dermatol. 2025 Dec 10:ljaf516. doi: 10.1093.
    >> Share

  40. ZHAO P, Chew C, Szeto P, Berry W, et al
    Genomic copy number burden distinguishes the diagnosis and prognosis of primary dermal melanoma.
    Br J Dermatol. 2025 Dec 9:ljaf507. doi: 10.1093.
    >> Share

    November 2025
  41. KNOPFEL N, Barberan-Martin S, Polubothu S, Sauvadet A, et al
    Gene discovery in extensive dermal melanocytosis reveals multiple mosaic causes.
    Br J Dermatol. 2025 Nov 27:ljaf481. doi: 10.1093.
    >> Share

  42. MARJANOVIC M, Mikiver R, Nielsen K, Isaksson K, et al
    Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma: A Nationwide Population-Based Registry Study from Sweden.
    Br J Dermatol. 2025 Nov 26:ljaf478. doi: 10.1093.
    >> Share

  43. SIEBORG J, Zwahlen D, Maul JT, Haedersdal M, et al
    Psychological distress and unmet supportive care needs in melanoma-survivors and high-risk patients for melanoma: A Swiss cross-sectional study.
    Br J Dermatol. 2025 Nov 5:ljaf439. doi: 10.1093.
    >> Share

  44. KAHLER S, Primiero C, Mothershaw A, Jayasinghe D, et al
    3D-total body photography identifies cutaneous phenotypes associated with late-onset invasive melanoma risk.
    Br J Dermatol. 2025 Nov 3:ljaf440. doi: 10.1093.
    >> Share

  45. LIU Y, Tan L
    A Missing Piece in the Cutaneous Melanoma Puzzle: Metabolic Reprogramming Driven by Loss of TET2/5hmC.
    Br J Dermatol. 2025 Nov 3:ljaf442. doi: 10.1093.
    >> Share

    October 2025
  46. LEE KJ, Kao YC, Jiang A, Prokofyeva A, et al
    Subclinical Fields of BRAF V600E-Mutant Melanocytes Populate Human Skin and Are Enriched Around Melanoma and Naevi.
    Br J Dermatol. 2025 Oct 28:ljaf412. doi: 10.1093.
    >> Share

  47. YOSHINO K, Fujisawa Y, Yoshikawa S, Maekawa T, et al
    Nivolumab in the treatment of non-melanoma skin cancer: multi-center, retrospective analysis of 46 cases.
    Br J Dermatol. 2025 Oct 27:ljaf420. doi: 10.1093.
    >> Share

  48. MISTRY K, Bagdatoglou G, Daniels S, Lorigan P, et al
    The economic burden of melanoma in the UK: A stage-specific cost analysis underscoring the importance of prevention and early diagnosis.
    Br J Dermatol. 2025 Oct 22:ljaf393. doi: 10.1093.
    >> Share

  49. ZHU G, Gordon S, Green AC, Martin NG, et al
    Halving of Australian children's naevus counts during 1992-2016 and change in sun behaviour.
    Br J Dermatol. 2025;193:898-906.
    >> Share

    September 2025
  50. FISCHER GM, Fang R, Xu S, Karkempetzaki AI, et al
    Loss of TET2 Facilitates Aggressive Behavior in Cutaneous Melanoma by Inducing PGC1alpha/Oxidative Phosphorylation (OXPHOS).
    Br J Dermatol. 2025 Sep 27:ljaf378. doi: 10.1093.
    >> Share

  51. WHITEMAN DC
    BRAF testing for melanoma in England.
    Br J Dermatol. 2025 Sep 12:ljaf373. doi: 10.1093.
    >> Share

  52. AHMED S, van Bodegraven B, Proby C, Harwood CA, et al
    Ethnicity and the epidemiology of skin cancer incidence: a national retrospective population-based study in England, 2013-20.
    Br J Dermatol. 2025 Sep 10:ljaf352. doi: 10.1093.
    >> Share

  53. HAFERKAMP S, Schilling B, Berking C, Drexler K, et al
    Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma - Results of a multicenter phase II study.
    Br J Dermatol. 2025 Sep 4:ljaf350. doi: 10.1093.
    >> Share

  54. MISTRY K, Jeffrey P, Levell NJ, Kennedy O, et al
    A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21.
    Br J Dermatol. 2025 Sep 3:ljaf351. doi: 10.1093.
    >> Share

    July 2025
  55. NARDIN C, Cavalieri C, Lebbe C, Gerard E, et al
    Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
    Br J Dermatol. 2025 Jul 14:ljaf268. doi: 10.1093.
    >> Share

  56. KARPONIS D, Mistry K, Stratigos G, Levell NJ, et al
    Can the effects of the COVID-19 pandemic provide insights into the impact of melanoma under-diagnosis and delayed care?
    Br J Dermatol. 2025 Jul 3:ljaf263. doi: 10.1093.
    >> Share

    June 2025
  57. BAI X, Flaherty KT
    The Rise of New Targets in Melanoma.
    Br J Dermatol. 2025 Jun 26:ljaf251. doi: 10.1093.
    >> Share

  58. ALANI O, Ahmed A, Haraldsdottir EL, Hoyt D, et al
    The Incidence and Impact of Melanoma Subtypes in Iceland 1955-2023.
    Br J Dermatol. 2025 Jun 23:ljaf248. doi: 10.1093.
    >> Share

  59. KAHLER S, Primiero C, Jayasinghe D, Mothershaw A, et al
    Unpredictable interdependence of invasive and in situ melanoma.
    Br J Dermatol. 2025 Jun 19:ljaf235. doi: 10.1093.
    >> Share

  60. SIA T, Li S, Zhong X, Park C, et al
    Acitretin chemoprevention in non-melanoma skin cancer patients with chronic hematopoietic disease: findings from three independent databases.
    Br J Dermatol. 2025 Jun 10:ljaf221. doi: 10.1093.
    >> Share

  61. LIU X, McBride JD
    Unmethylated PRAME DNA in Tissue and Plasma: A Promising Marker for Melanoma.
    Br J Dermatol. 2025 Jun 3:ljaf217. doi: 10.1093.
    >> Share

    May 2025
  62. WANG Y, Xu G, Xia H
    Targeting the MAPK Pathway for NRAS Mutant Melanoma: From Mechanism to Clinic.
    Br J Dermatol. 2025 May 9:ljaf178. doi: 10.1093.
    >> Share

  63. WHITEMAN DC
    Melanoma in England: incidence is up, mortality is down.
    Br J Dermatol. 2025 May 7:ljaf175. doi: 10.1093.
    >> Share

  64. ZHANG WW, Ke LF, Chen Y, Wu CY, et al
    Methylation-Based Test for Diagnosis of Benign and Malignant Melanocytoma.
    Br J Dermatol. 2025 May 2:ljaf169. doi: 10.1093.
    >> Share

    April 2025
  65. KARPONIS D, van Bodegraven B, Mistry K, Nikolaou V, et al
    Incidence and mortality of melanoma in situ and malignant melanoma in England between 2001 and 2020.
    Br J Dermatol. 2025 Apr 15:ljaf136. doi: 10.1093.
    >> Share

    March 2025
  66. KOCHI Y, Togawa Y, Yamazaki Y, Yamamoto Y, et al
    Anatomical distribution of acral lentiginous melanoma in the hand and nail among Japanese individuals.
    Br J Dermatol. 2025 Mar 4:ljaf070. doi: 10.1093.
    >> Share

    February 2025
  67. ACKERMANN DM, Bell KJL
    Setting the melanoma research agenda for all end-users: the need to include patient, clinician, and policy perspectives.
    Br J Dermatol. 2025 Feb 27:ljaf082. doi: 10.1093.
    >> Share

  68. NARDIN C, Vernerey D, Aubin F
    Ipilimumab + nivolumab combination or nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort.
    Br J Dermatol. 2025 Feb 27:ljaf080. doi: 10.1093.
    >> Share

  69. MISTRY K, Srimudkul O, Patel M, Ragan J, et al
    Patient research priorities in melanoma: a national qualitative interview study.
    Br J Dermatol. 2025 Feb 27:ljaf048. doi: 10.1093.
    >> Share

  70. DELCOIGNE B, Lysell J, Askling J
    Incidence, stage and outcome of melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks?
    Br J Dermatol. 2025 Feb 25:ljaf074. doi: 10.1093.
    >> Share

  71. LOPEZ S, Thakker S, Minkis K
    Beyond the Diagnosis: A Skin of Color Patient's Journey with Acral Lentiginous Melanoma.
    Br J Dermatol. 2025 Feb 6:ljaf047. doi: 10.1093.
    >> Share

    January 2025
  72. EGGERMONT CJ, Hollatz A, Wakkee M, Louwman M, et al
    Skin cancer risk in over 200.000 patients with haematologic malignancies in 30 years; a nationwide population-based study in the Netherlands.
    Br J Dermatol. 2025 Jan 24:ljaf027. doi: 10.1093.
    >> Share

  73. SMITH MJ, Peach H, Keohane S, Lear J, et al
    Melanoma: Assessment and Management summary of 2022 update of the NICE guidelines.
    Br J Dermatol. 2025 Jan 21:ljaf016. doi: 10.1093.
    >> Share

  74. ANDERSON ADG, Shirwac HF, Morgan H, Greenish H, et al
    Real-World Melanoma Miss-Rate In An NHS Hospital Dermatology Service. A Retrospective Study.
    Br J Dermatol. 2025 Jan 16:ljaf024. doi: 10.1093.
    >> Share

    December 2024
  75. PLACKE JM, Bottek J, Varaljai R, Shannan B, et al
    Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma.
    Br J Dermatol. 2024 Dec 31:ljae433. doi: 10.1093.
    >> Share

  76. WHITEMAN DC, Pandeya N, Olsen CM
    Differences in mean age at diagnosis of invasive melanoma for men and women, by anatomic site, thickness, and subtype.
    Br J Dermatol. 2024 Dec 17:ljae482. doi: 10.1093.
    >> Share

    November 2024
  77. KARINE B, Mortier L, Dereure O, Dalac S, et al
    The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab versus nivolumab in a real-world setting.
    Br J Dermatol. 2024 Nov 28:ljae470. doi: 10.1093.
    >> Share

  78. WOLBER AK, Jayasinghe D, Betz-Stablein B, Janda M, et al
    Incidence and patterns of newly developed pigmented lesions in adults at high risk for melanoma.
    Br J Dermatol. 2024 Nov 26:ljae467. doi: 10.1093.
    >> Share

  79. ZHENG DX, Jenkins RW
    Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma.
    Br J Dermatol. 2024 Nov 15:ljae445. doi: 10.1093.
    >> Share

  80. SANGERS TE, van Doorn R
    The usefulness of large language models for patient information on melanoma: challenges and opportunities.
    Br J Dermatol. 2024 Nov 1:ljae429. doi: 10.1093.
    >> Share

    October 2024
  81. WELLER RB, Gu J
    Ultraviolet radiation is not the major cause of melanoma mortality in the UK and sun exposure advice should be revised.
    Br J Dermatol. 2024 Oct 30:ljae426. doi: 10.1093.
    >> Share

  82. RAUWERDINK DJW, Hoogland Y, Schrader AMR, Potjer TP, et al
    Melanoma arising from pre-existing naevus in carriers of a germline CDKN2A pathogenic variant.
    Br J Dermatol. 2024 Oct 29:ljae417. doi: 10.1093.
    >> Share

  83. MCGILLIVRAY E, Ashouri K, Chatziioannou E, Gallegos JAO, et al
    Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.
    Br J Dermatol. 2024 Oct 23:ljae401. doi: 10.1093.
    >> Share

  84. KAMMINGA NC, Kievits JE, Plaisier PW, Burgers JS, et al
    Do Large Language Model Chatbots perform better than established patient information resources in answering patient questions? A comparative study on melanoma.
    Br J Dermatol. 2024 Oct 4:ljae377. doi: 10.1093.
    >> Share

  85. PANDEYA N, Olsen CM, Neale RE, Whiteman DC, et al
    Melanoma as a detection-dependent cancer: proxy measures of screening and surveillance associated with 3-year incidence of detection procedures for skin cancer in a national prospective study.
    Br J Dermatol. 2024 Oct 1:ljae372. doi: 10.1093.
    >> Share

    September 2024
  86. STEVENS HP, Pellacani G, Angus C, El-Jabbour JN, et al
    The use of Reflectance Confocal Microscopy to diagnose Malignant Melanoma and Lentigo Maligna in the United Kingdom: A Prospective Observational Trial at a Single Centre.
    Br J Dermatol. 2024 Sep 10:ljae354. doi: 10.1093.
    >> Share

  87. MAHUMUD RA
    The emerging burden of melanoma overdiagnosis in Australia: Who bears the cost-patients or the healthcare system?
    Br J Dermatol. 2024 Sep 9:ljae339. doi: 10.1093.
    >> Share

  88. POSADA V, Toland AE
    Role of albinism and pigment-related genes in amelanotic melanoma formation.
    Br J Dermatol. 2024 Sep 9:ljae353. doi: 10.1093.
    >> Share

  89. GELLER AC, Stratigos AJ
    Exploring sex and site- specific differences in melanoma.
    Br J Dermatol. 2024 Sep 4:ljae345. doi: 10.1093.
    >> Share

    August 2024
  90. YAMAZAKI E, Fujimura T, Takahashi-Watanabe M, Tada S, et al
    Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial.
    Br J Dermatol. 2024 Aug 31:ljae343. doi: 10.1093.
    >> Share

  91. STURM RA, Smit DJ, Duffy DL, McLean C, et al
    Uncovering molecular mechanisms for amelanotic/hypopigmented primary cutaneous melanoma.
    Br J Dermatol. 2024 Aug 21:ljae336. doi: 10.1093.
    >> Share

    July 2024
  92. VAN DOORN R
    Supplemental vitamin D on trial: no evidence of benefit as an adjuvant treatment for melanoma.
    Br J Dermatol. 2024 Jul 23:ljae302. doi: 10.1093.
    >> Share

  93. LINDSAY D, Bell KJL, Olsen CM, Whiteman DC, et al
    Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.
    Br J Dermatol. 2024 Jul 19:ljae296. doi: 10.1093.
    >> Share

  94. OLSEN CM, Pandeya N, Neale RE, Law MH, et al
    Phenotypic and genotypic risk factors for invasive melanoma by sex and body site.
    Br J Dermatol. 2024 Jul 19:ljae297. doi: 10.1093.
    >> Share

  95. LALLAS K, Spyridonos P, Kittler H, Tschandl P, et al
    Prediction of melanoma metastasis using dermatoscopy deep features. An international multicenter cohort study.
    Br J Dermatol. 2024 Jul 12:ljae281. doi: 10.1093.
    >> Share

  96. KLEEMANN J, Schilling B
    Multicenter phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in japanese advanced melanoma patients: Immune resistance remains one of the major efforts in melanoma research.
    Br J Dermatol. 2024 Jul 2:ljae279. doi: 10.1093.
    >> Share

    June 2024
  97. DE SMEDT J, Van Kelst S, Janssen L, Marasigan V, et al
    High dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind, placebo-controlled study (ViDMe trial).
    Br J Dermatol. 2024 Jun 24:ljae257. doi: 10.1093.
    >> Share

  98. MCMAHON M, Deacon DC
    Spatial sequencing reveals transcriptional variation between amelanotic and pigmented acral melanoma.
    Br J Dermatol. 2024 Jun 15:ljae253. doi: 10.1093.
    >> Share

  99. FUJIMURA T, Yoshino K, Kato H, Fukushima S, et al
    Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial.
    Br J Dermatol. 2024 Jun 4:ljae231. doi: 10.1093.
    >> Share

    May 2024
  100. CHOI ME, Choi EJ, Lee JH, Won CH, et al
    Spatial transcriptome analysis of amelanotic acral melanoma reveals distant molecular determinants compared to pigmented acral melanoma.
    Br J Dermatol. 2024 May 30:ljae224. doi: 10.1093.
    >> Share

  101. HANRAHAN GB, Tsibris HC
    Mutational Landscape and Tumor Mutational Burden in Adult Patients with Malignant Melanoma Arising From Congenital Nevi.
    Br J Dermatol. 2024 May 21:ljae214. doi: 10.1093.
    >> Share

  102. OLSEN CM
    Ecological evidence for melanoma overdiagnosis in Denmark.
    Br J Dermatol. 2024 May 16:ljae206. doi: 10.1093.
    >> Share

    April 2024
  103. NIELSEN JB, Kristiansen IS, Thapa S
    Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?
    Br J Dermatol. 2024 Apr 24:ljae175. doi: 10.1093.
    >> Share


  104. A novel strategy for the treatment of melanoma.
    Br J Dermatol. 2024;190:e51.
    >> Share


  105. Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment.
    Br J Dermatol. 2024;190:e58.
    >> Share

  106. JONES OT, Matin RN, Walter FM
    Using artificial intelligence-based technologies to support the diagnosis and early detection of melanoma in primary care.
    Br J Dermatol. 2024 Apr 9:ljae094. doi: 10.1093.
    >> Share

    March 2024
  107. TALTY R, Richmond R, Micevic G
    Melanoma TIL therapy commences era of cell-based immunotherapies.
    Br J Dermatol. 2024 Mar 22:ljae126. doi: 10.1093.
    >> Share


  108. AMBRA1 and loricrin as a test to identify low-risk early-stage melanoma.
    Br J Dermatol. 2024;190:e46.
    >> Share


  109. International trends in the incidence of cutaneous squamous cell carcinoma and melanoma.
    Br J Dermatol. 2024;190:e40.
    >> Share

    February 2024
  110. RIBERO S, Quaglino P, Roccuzzo G
    Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
    Br J Dermatol. 2024 Feb 29:ljae092. doi: 10.1093.
    >> Share

  111. EGELER MD, Ryll B
    Survival is not enough: understanding the mental burden of cutaneous melanoma.
    Br J Dermatol. 2024 Feb 3:ljae050. doi: 10.1093.
    >> Share

    January 2024
  112. MUKHTAR AB, Morgan HJ, Gibbs A, Davies GE, et al
    Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
    Br J Dermatol. 2024 Jan 30:ljad502. doi: 10.1093.
    >> Share

  113. BERGAMASCHI D
    Improving cancer stem cells killing in malignant melanoma.
    Br J Dermatol. 2024 Jan 29:ljae035. doi: 10.1093.
    >> Share


  114. Risk factors for developing a new primary melanoma in people with a melanoma.
    Br J Dermatol. 2024;190:e15.
    >> Share


  115. Genes associated with nodular melanoma.
    Br J Dermatol. 2024;190:e18.
    >> Share

  116. PAPACHRISTOU P, Soderholm M, Pallon J, Taloyan M, et al
    Evaluation of an artificial intelligence-based decision support for detection of cutaneous melanoma in primary care - a prospective, real-life, clinical trial.
    Br J Dermatol. 2024 Jan 17:ljae021. doi: 10.1093.
    >> Share

  117. PENA-MARTIN J, Garcia-Ortega MB, Palacios-Ferrer JL, Diaz C, et al
    Identification of novel biomarkers for early diagnosis of malignant melanoma by untargeted LC-HRMS-based metabolomics: a pilot study.
    Br J Dermatol. 2024 Jan 12:ljae013. doi: 10.1093.
    >> Share

  118. COCCIMIGLIO M, Chiodo F, van Kooyk Y
    The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
    Br J Dermatol. 2024 Jan 10:ljad517. doi: 10.1093.
    >> Share

  119. KUNGWENGWE G, Gowthorpe C, Ali SR, Warren H, et al
    Prevalence & Odds of Anxiety & Depression in Cutaneous Malignant Melanoma: A Proportional Meta-analysis & Regression.
    Br J Dermatol. 2024 Jan 10:ljae011. doi: 10.1093.
    >> Share

    December 2023

  120. Genetics and melanoma screening.
    Br J Dermatol. 2023;190:e4.
    >> Share

  121. EGGERMONT CJ, Eggermont AMM
    Shifting landscape in skin cancer incidence: the rising tide of cutaneous squamous cell carcinoma and potential implications for prevention.
    Br J Dermatol. 2023 Dec 14:ljad480. doi: 10.1093.
    >> Share

    November 2023
  122. MOHR C, Li Y, Navsaria LJ, Hinkston CL, et al
    Melanoma risk in skin of color patients with a history of a keratinocyte carcinoma.
    Br J Dermatol. 2023 Nov 30:ljad474. doi: 10.1093.
    >> Share

  123. EWEN T, Husain A, Stefanos N, Barrett P, et al
    Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
    Br J Dermatol. 2023 Nov 25:ljad459. doi: 10.1093.
    >> Share

  124. KAMMINGA NCW, Wakkee M, Swart I, Nijsten TEC, et al
    Determining the core content of a digital survivorship care plan for melanoma survivors: A multi-stakeholder Delphi-consensus study.
    Br J Dermatol. 2023 Nov 18:ljad450. doi: 10.1093.
    >> Share

  125. DESSINIOTI C, Stratigos AJ
    Decoding the nodular melanoma subtype- what about genetics?
    Br J Dermatol. 2023 Nov 17:ljad445. doi: 10.1093.
    >> Share


  126. Survival trends in people with melanoma in Sweden.
    Br J Dermatol. 2023;189:e108.
    >> Share

  127. SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
    Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors.
    Br J Dermatol. 2023 Nov 8:ljad342. doi: 10.1093.
    >> Share

  128. SMIT AK, Cust AE
    Unpacking factors contributing to melanoma overdiagnosis: does polygenic risk play a role?
    Br J Dermatol. 2023 Nov 6:ljad431. doi: 10.1093.
    >> Share

    October 2023
  129. OLSEN CM, Pandeya N, Ragaini BS, Neale RE, et al
    International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020.
    Br J Dermatol. 2023 Oct 27:ljad425. doi: 10.1093.
    >> Share

  130. AUTIER P
    Melanoma incidence and COVID-19 lockdowns in the Netherlands.
    Br J Dermatol. 2023 Oct 4:ljad376. doi: 10.1093.
    >> Share

    September 2023
  131. STARK MS, Sturm RA, Pan Y, Smit DJ, et al
    Assessing the genetic risk of nodular melanoma using a candidate gene approach.
    Br J Dermatol. 2023 Sep 28:ljad365. doi: 10.1093.
    >> Share

  132. VAN DOORN R
    Multiple Primary Melanoma: Risk Factors Reviewed.
    Br J Dermatol. 2023 Sep 15:ljad343. doi: 10.1093.
    >> Share


  133. Features of very thin melanoma that predict lymph node involvement.
    Br J Dermatol. 2023;189:e74.
    >> Share

  134. GUERRERO-JUAREZ CF, Goyal PK, Amber KT
    Targeting IL-4/IL-13 in immune checkpoint inhibitor induced bullous pemphigoid: a cautionary note on the beneficial effect of Th2 in melanoma and immunotherapy.
    Br J Dermatol. 2023 Sep 13:ljad324. doi: 10.1093.
    >> Share

  135. PANDEYA N, Dusingize JC, Olsen CM, MacGregor S, et al
    Does genetic risk modify the effect of skin screening on melanoma detection rates?
    Br J Dermatol. 2023 Sep 8:ljad333. doi: 10.1093.
    >> Share

    August 2023

  136. Correction to: Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
    Br J Dermatol. 2023 Aug 24:ljad288. doi: 10.1093.
    >> Share


  137. Validation of a blood test for melanoma.
    Br J Dermatol. 2023;189:e65.
    >> Share

  138. CLAESON M
    Real-world data show improved melanoma survival in Sweden.
    Br J Dermatol. 2023 Aug 24:ljad309. doi: 10.1093.
    >> Share

  139. SMITH J, Cust AE, Lo SN
    Risk factors for subsequent primary melanoma for patients with previous melanoma: A systematic review and meta-analysis.
    Br J Dermatol. 2023 Aug 10:ljad275. doi: 10.1093.
    >> Share

    July 2023
  140. PAN CX, Kim DY, Lau CB, Lau WC, et al
    Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: A retrospective cohort study.
    Br J Dermatol. 2023 Jul 28:ljad271. doi: 10.1093.
    >> Share

  141. VIKSTROM S, Mikiver R, Lapins J, Nielsen K, et al
    Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
    Br J Dermatol. 2023 Jul 18:ljad244. doi: 10.1093.
    >> Share

  142. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    >> Share

  143. GIUFFRIDA R, Zanin Poletto G, Guarneri F, Conforti C, et al
    Nevus count on the face for the identification of patients with higher risk of melanoma.
    Br J Dermatol. 2023 Jul 6:ljad216. doi: 10.1093.
    >> Share

  144. RIBERO S, Quaglino P, Roccuzzo G
    Predicting progression in very thin melanoma: the challenge of the next decade?
    Br J Dermatol. 2023 Jul 3:ljad218. doi: 10.1093.
    >> Share

    June 2023
  145. KAKISH H, Sun J, Zheng DX, Ali Ahmed F, et al
    Predictors of Sentinel Lymph Node Metastasis in Very Thin Invasive Melanomas.
    Br J Dermatol. 2023 Jun 8:ljad195. doi: 10.1093.
    >> Share

  146. VERGARA IA, Stark MS
    One Step Closer to Improving Melanoma Diagnosis and Prognosis with Liquid Biopsies.
    Br J Dermatol. 2023 Jun 3:ljad185. doi: 10.1093.
    >> Share

    May 2023
  147. MUTO Y, Kambayashi Y, Kato H, Fukushima S, et al
    Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results.
    Br J Dermatol. 2023 May 27:ljad183. doi: 10.1093.
    >> Share


  148. Two melanoma genes (MITF and MC1R) interact to cause different risks.
    Br J Dermatol. 2023;188:e44.
    >> Share

  149. POGORZELSKA-DYRBUS J, Szepietowski JC
    Melanoma cells in optical super-high magnification dermoscopy.
    Br J Dermatol. 2023 May 22:ljad168. doi: 10.1093.
    >> Share

  150. VAN LAAR R, Latif B, King S, Love C, et al
    Validation of microRNA Liquid Biopsy for Diagnosis and Risk Stratification of Invasive Cutaneous Melanoma.
    Br J Dermatol. 2023 May 5:ljad137. doi: 10.1093.
    >> Share

    April 2023
  151. LALLAS A
    Which melanoma patients are at priority for monitoring to detect new primary melanoma?
    Br J Dermatol. 2023 Apr 17:ljad125. doi: 10.1093.
    >> Share

  152. IBRAHIM LS, Venables ZC, McPhail S, Levell NJ, et al
    Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019.
    Br J Dermatol. 2023 Apr 10:ljad117. doi: 10.1093.
    >> Share

  153. FUJISAWA Y, Namikawa K, Yoshino K, Kiniwa Y, et al
    Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases.
    Br J Dermatol. 2023 Apr 5:ljad114. doi: 10.1093.
    >> Share

    March 2023

  154. Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
    Br J Dermatol. 2023;188:e29.
    >> Share

  155. ASCOTT A, van Bodegraven B, Vernon S, Orteu CH, et al
    The geographical variation of melanoma, basal and squamous cell carcinoma in England.
    Br J Dermatol. 2023 Mar 30:ljad100. doi: 10.1093.
    >> Share

  156. ARACTINGI S, Oules B
    Correcting 'false' warnings with new tools? An illustrative example.
    Br J Dermatol. 2023;188:452.
    >> Share

  157. BRUNO W
    Joint contribution of MC1R and MITF alleles to melanoma risk in the age of polygenic risk scores.
    Br J Dermatol. 2023 Mar 28:ljad097. doi: 10.1093.
    >> Share

  158. NI Y, Watts CG, Scolyer RA, Madronio C, et al
    Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
    Br J Dermatol. 2023 Mar 22:ljad076. doi: 10.1093.
    >> Share

  159. WALLINGFORD CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, et al
    MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
    Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093.
    >> Share

  160. OLSEN CM, Gordon LG, Carter SM, Whiteman DC, et al
    The ethical implications of opportunistic detection of melanoma in clinical care.
    Br J Dermatol. 2023 Mar 3:ljad055. doi: 10.1093.
    >> Share

  161. GHIASVAND R, Berge LAM, Andreassen BK, Green AC, et al
    Statin use and risk of cutaneous melanoma: A nationwide nested case-control study.
    Br J Dermatol. 2023 Mar 3:ljad057. doi: 10.1093.
    >> Share

    February 2023
  162. VAN BODEGRAVEN B, Vernon S, Eversfield C, Board R, et al
    "Get Data Out" Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
    Br J Dermatol. 2023 Feb 23:ljad033. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016